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Abstract
Background: Transdermal drug delivery has become an important means of drug administration.
It presents numerous advantages but it is still limited by the small number of drugs with a suitable
profile. The use of solvents that affect the skin barrier function is one of the classic strategies of
penetration enhancement. Some of these solvents have well characterised actions on the stratum
corneum, but the majority are still selected using empirical criteria. The objective of this work was
to conduct a systematic study on the ability to affect skin permeation of solvents commonly used
in transdermal formulations. An innovative methodology in this area was employed, consisting of
the combination of skin surface biopsy with colorimetry.
Methods: The study compared in vivo differences in the permeation of a hydrophilic (methylene
blue) and a lipophilic (Sudan III) dye, after treatment of the skin with different vehicles. Consecutive
skin surface biopsies of each site were taken and the cumulative amounts of the dyes in the stripped
stratum corneum were measured by reflectance colourimetry.
Results: Results indicate that the amount of methylene blue present in the stratum corneum
varied significantly with different skin pre-treatments. Some solvents provided a 1.5 fold
penetration enhancement but others decreased by almost half the permeation of the dye. The
permeation of Sudan III was less significantly affected by solvent pre-treatment.
Conclusions: This study has only superficially explored the potential of the combination of skin
surface biopsy and colourimetry, but the encouraging results obtained confirm that the
methodology can be extended to the study of more complex formulations.
Background
Transdermal drug delivery (TDD) has become an impor-
tant means of drug administration. When compared to
the more conventional drug delivery strategies TDD
presents numerous advantages [1]: (a) avoidance of the
variation in the absorption and metabolism associated
with oral administration, (b) avoidance of the risks and
inconveniences of injection, (c) permits continuous zero-
order drug administration and the use of drugs with short
biological half-lives, (d) increases the bioavailability and
efficacy of drugs since hepatic first-pass elimination is
bypassed and, finally, (e) provides a simple therapeutic
regime, leading to good patient compliance, that can be
easily terminated by simple removal of the patch.
Nevertheless, the skin is an efficient barrier to the ingress
of materials, which limits TDD to molecules with an ade-
quate balance between lipophilic and hydrophilic charac-
teristics, and an appropriate molecular size [2]. Different
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approaches to penetration enhancement have been devel-
oped to overcome these difficulties.
Classic physical penetration enhancement strategies
include iontophoresis [3], electroporation [4], phono-
phoresis [5-7] or supersaturated solutions [8,9], but
recently novel approaches have been developed such as
compressed gas propulsion [10] and the use of microfab-
ricated microneedles to pierce the stratum corneum [11].
Several chemical substances have been shown to possess
the ability to enhance permeation across the skin, and are
therefore commonly included in transdermal systems.
These include low molecular weight alcohols [12], alkyl
methanol sulphoxides [13], non ionic surfactants [14]
(polysorbates, polyethoxylated alkyl ethers and esters and
poloxamers), oleic acid in synergy with propylene glycol
[15,16] and azone [17,18]. In spite of the wide use of
chemical enhancers, there are still few guidelines for their
rational choice and the exact mechanisms of action in the
skin have not yet been fully established. In this context,
the skin surface biopsy (SSB) technique can be regarded as
an innovative strategy in the study of transcutaneous pen-
etration. This simple and versatile approach to the study
of the stratum corneum was introduced by Goldschmidt
and Kligman in the 1960's [19] and was later developed
by Marks and Dawber [20]. If consecutive biopsies are per-
formed in the same area it becomes possible to follow the
permeation of a compound through the stratum corneum
[21,22]. SSB alone does not provide any data regarding
the amount of chemical permeated through the epidermis
and dermis into systemic circulation, but it can be com-
bined with the determination of blood and urine concen-
tration in pharmacokinetic studies. Corneosurfametry is
also a technique that relies on SSB to assess the impact on
the stratum corneum of surfactants used in cosmetics
[23].
The aim of the present study is to conduct a systematic in
vivo study of the influence on percutaneous penetration of
solvents commonly used as vehicles in transdermal sys-
tems. Differences in the permeation of two model per-
meant (methylene blue and Sudan III-the first with
hydrophilic characteristics and the latter more lipophilic)
after skin pre-treatment with the different solvents, were
assessed using SSB and colourimetry [24].
Material and methods
Subjects
Five male and 5 female caucasian volunteers with normal
healthy skin were used, and were fully informed of the
nature of the study and of the procedures involved. The
study was approved by the local ethics committee and is
in compliance with the Helsinki Declaration. The age
range was 21–28 years. Four sites were marked in each
volar forearm of the volunteer and assigned at random: 1
site served as control and the other 7 were pre-treated with
different vehicles.
Skin pre-treatment and vehicle application
Filter paper discs 15 mm in diameter were impregnated
with each vehicle and applied to the previously assigned
pre-treatment sites. Both treated and untreated (control)
sites were then covered for 1 hour with Parafilm™ held in
place with self-adhesive fabric. The following solvents
were used in the pre-treatment:
• Oleic acid (Merck, Germany),
• Isopropyl myristate (Merck, Germany),
• Octanol (Merck, Germany),
• Polyethylene glycol 400 (PEG 400) (Fisher Scientific,
UK),
• Propylene glycol (Fisher Scientific, UK),
• Octanol: propylene glycol 1:1,
• Oleic acid: propylene glycol 1:1.
After this time the "chambers" were removed and replaced
by others containing filter paper discs soaked with satu-
rated solutions of either methylene blue (aqueous) or
Sudan III (ethanol) (Merck, Germany), that were left in
contact with the skin for 4 hours. The procedure was
stopped at the end of the application time, and excess dye
was gently washed with warm water.
Skin surface biopsy
A drop of the adhesive glue was placed on a glass slide
which was then placed over the skin, covered with a 200 g
cylinder to ensure that constant pressure was applied, for
5 minutes [20]. After this time the slide was quickly
removed and the colourimetry measurement was per-
formed on the resulting biopsy. This entire procedure was
performed twice on each of the previously assigned sites
(control and treated).
Colourimetry
The CIELAB (Commission Internationale de l'Eclairage
L*a*b*) colour space system is widely used in cosmetol-
ogy and dermatology [25]. It enables a quantitative char-
acterization of a colour using a three-dimensional axis,
where L* represents lightness and a* and b* represent hue
and chroma. The intensity of dye in each biopsy slide was
measured using a Chroma Meter CR-300 (Minolta, Osaka,
Japan), following published guidelines [26]. The parame-
ter a* reflects the red chromaticity and was therefore used
to quantify the intensity of Sudan III whereas the b*BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/5
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parameter was used for methylene blue. Both parameters
are expressed in arbitrary units. The cumulative intensity
of colour in each site was then calculated by adding the
values of a* or [b]* obtained after the corresponding first
and second biopsies.
Statistical analysis
Descriptive statistics and non-parametric comparative
analysis (Wilcoxon sign rank test) were used in this study.
A 0.05 significance level was adopted.
Results
As can be seen in Figure 1, the cumulative intensity of
Sudan III present in the stratum corneum was higher
when the skin was pre-treated with oleic acid, octanol and
Cumulative a* values (arbitrary units) obtained after applica- tion of Sudan III and different solvent treatments (mean ±  SD) IPM-isopropyl myristate; oct/PG-octanol: propylene gly- col 1:1; AO/PG – oleic acid: propylene glycol 1:1; PG – pro- pylene glycol Figure 1
Cumulative a* values (arbitrary units) obtained after applica-
tion of Sudan III and different solvent treatments (mean ± 
SD) IPM – isopropyl myristate; oct/PG – octanol: propylene 
glycol 1:1; AO/PG – oleic acid: propylene glycol 1:1; PG – 
propylene glycol. Statistical differences between pre-treat-
ment and control results represented by * (p < 0.01), ** (p < 
0.05) and NS (no statistical difference)
Enhancement ratio of Sudan III provided by different solvent  treatments (mean ± SD) IPM – isopropyl myristate; oct/PG –  octanol: propylene glycol 1:1; AO/PG – oleic acid: propylene  glycol 1:1; PG – propylene glycol Figure 2
Enhancement ratio of Sudan III provided by different solvent 
treatments (mean ± SD) IPM – isopropyl myristate; oct/PG – 
octanol: propylene glycol 1:1; AO/PG – oleic acid: propylene 
glycol 1:1; PG – propylene glycol.
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Cumulative |b|* values (arbitrary units) obtained after appli- cation of methylene blue and different solvent treatments  (mean ± SD) IPM – isopropyl myristate; oct/PG – octanol:  propylene glycol 1:1; AO/PG – oleic acid: propylene glycol  1:1; PG – propylene glycol Figure 3
Cumulative |b|* values (arbitrary units) obtained after appli-
cation of methylene blue and different solvent treatments 
(mean ± SD) IPM – isopropyl myristate; oct/PG – octanol: 
propylene glycol 1:1; AO/PG – oleic acid: propylene glycol 
1:1; PG – propylene glycol. Statistical differences between 
pre-treatment and control results represented by * (p < 
0.01), ** (p < 0.05) and NS (no statistical difference)
Enhancement ratio of methylene blue provided by different  solvent treatments (mean ± SD) IPM – isopropyl myristate;  oct/PG – octanol: propylene glycol 1:1; AO/PG – oleic acid:  propylene glycol 1:1; PG – propylene glycol Figure 4
Enhancement ratio of methylene blue provided by different 
solvent treatments (mean ± SD) IPM – isopropyl myristate; 
oct/PG – octanol: propylene glycol 1:1; AO/PG – oleic acid: 
propylene glycol 1:1; PG – propylene glycol.
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propylene glycol (PG) than in the control where the skin
was not treated. There was a modest increase when the
skin was pre-treated with a mixture of oleic acid 5% and
propylene glycol (AO/PG).
The enhancement ratios provided by each vehicle (vehicle
cumulative a*/ control cumulative a*) are represented in
Figure 2. None of the vehicles used in the pre-treatment
yielded ratios that are significantly higher than one.
The effect of vehicle pre-treatment was more pronounced
in the permeation of methylene blue, which increased sig-
nificantly after pre-treatment with oleic acid, octanol and
the oleic acid/PG mixture. Interestingly, it also decreased
when isopropyl myristate (IPM) and polyethylene glycol
400 (PEG 400) were used (Figure 3).
The vehicle cumulative [b*] / control cumulative [b*]
ratios obtained for methylene blue confirm that permea-
tion was enhanced when oleic acid, octanol and oleic
acid/PG were used (Figure 4). Pre-treatment with IPM and
PEG 400 seems to have hindered the permeation of meth-
ylene blue since the ratios are significantly lower than one.
Pre-treatment with an octanol and propylene glycol 1:1
mixture (oct/PG) had no impact in the permeation of
both Sudan III and methylene blue.
Statistical differences between the enhancement ratios of
all vehicle pre-treatments are represented in Tables 1 and
2. PEG 400 and IPM hindered the permeation of methyl-
ene blue and, therefore, more significant statistical differ-
ences were observed between the results provided by these
vehicles and the other solvents that acted as permeation
enhancers. For Sudan III, pre-treatments with propylene
glycol and IPM yielded enhancement ratios that presented
more significant differences to the other solvents.
Discussion
Several studies have been conducted on the influence of
vehicles in drug permeation. Most of them were per-
formed in vitro, using Franz cells and silastic membranes
or excised human epidermis [27-30]. The work conducted
in vivo has been based in methods that assess skin barrier
function, such as laser Doppler velocimetry [31] and tran-
sepidermal water loss measurements [32], or in more
invasive skin sampling techniques such as punch biopsy.
Oleic acid and propylene glycol are generally considered
classic penetration enhancers, increasing diffusivity
within the barrier membrane and/or vehicle drug
solubility-partitioning [33], and a synergy between these
vehicles as also been previously established [30,33]. The
results of our study are in agreement with the previously
reported findings, but a more marked effect was observed
for the hydrophilic permeant. Propylene glycol only
Table 1: Statistical differences between the results obtained for Sudan III. * indicates p < 0.01; ** indicates p < 0.05 and NS indicates 
there is no significant difference.
oleic acid IPM PEG 400 oct/PG OA/PG octanol PG
oleic acid
IPM *
PEG 400 * NS
octan/PG NS ** **
OA/PG NS ** ** **
octanol NS * * NS NS
PG NS * * NS NS NS
Table 2: Statistical differences between the results obtained for methylene blue. * indicates p < 0.01; ** indicates p < 0.05 and NS 
indicates there is no significant difference.
oleic acid IPM PEG 400 octan/PG OA/PG octanol PG
oleic acid
IPM *
PEG 400 * NS
oct/PG NS * NS
OA/PG NS * NS NS
octanol NS * * NS NS
PG * ** * NS ** **BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/5
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enhanced the permeation of methylene blue when
applied in a binary mixture. Low molecular weight alco-
hols have been shown to possess the ability to enhance
permeation across the skin. Their mechanism of action
seems to be related to stratum corneum lipid extraction,
particularly the more polar lipids [12]. The data in our
study showed that skin pre-treatment with octanol caused
an increase in the permeation of the two chemicals.
Conclusions
The work conducted aimed to investigate in vivo the influ-
ence of solvent pre-treatment in the permeation of a
lipophilic and a hydrophilic compound, using a combi-
nation of the versatile technique of skin surface biopsy
and colourimetry. Results showed that the two model per-
meants were influenced differently by the various treat-
ments and that it was possible to cause more significant
changes in the permeation of the hydrophilic molecule.
Cases of penetration enhancement but also of retarders
were observed. There was no simple correlation between
the properties of the solvent and permeation
enhancement.
The permeation of Sudan III was less significantly influ-
enced by any of the vehicles. Perhaps the partition of this
molecule into the stratum corneum is already high and
the vehicle pre-treatment did not significantly improve it.
This study has only superficially explored the potential of
the combination of skin surface biopsy and colorimetry,
but the encouraging results obtained confirm that the
methodology can be extended to the in vivo assessment of
more complex formulations.
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